Filters: Author is Anderson, G. [Clear All Filters]
Role of the FDA in affordability of off-patent pharmaceuticals. JAMA - Journal of the American Medical Association. 2016;315:461-462.
.
Reducing branded prescription drug prices: A review of policy options. Pharmacotherapy. 2017. Abstract
.
Life Expectancy in 2040: What Do Clinical Experts Expect?. North American Actuarial Journal. 2016;20:276-285. Abstract
.
Fairness in drug prices: do economists think differently from the public?. Health Econ Policy Law. 2018:1-12. Abstract
.
Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016. JAMA Intern Med. 2018;178:1451-1457. Abstract
.
Comparing the Value of Nonprofit Hospitals' Tax Exemption to Their Community Benefits. Inquiry. 2018;55:46958017751970. Abstract
.
Bridging the Silos of Service Delivery for High-Need, High-Cost Individuals. Popul Health Manag. 2016;19:421-428. Abstract
.
Branded prescription drug spending: a framework to evaluate policy options. J Pharm Policy Pract. 2017;10:31. Abstract
.